Single Nucleotide Polymorphisms in PPARD Associated with Systemic Lupus Erythematosus in Chinese Populations

Table 2

Stratification analysis for the association between PPARD rs4713853 polymorphism and SLE clinical manifestations.

Clinical manifestations		TT ()	CC+CT ()	value
Gender (male, %)		24 (5.6%)	47 (8.3%)	0.105
Onset age ()				0.266
Malar rash (+, %)		102 (23.8%)	149 (26.2%)	0.385
Discoid rash (+, %)		2 (0.5%)	5 (0.9%)	0.697
Photosensitivity (+, %)		14 (3.3%)	28 (4.9%)	0.197
Oral ulcers (+, %)		29 (6.8%)	43 (7.6%)	0.630
Nonerosive arthritis (+, %)		118 (27.5%)	160 (28.1%)	0.830
Pleuritis or pericarditis (+, %)		28 (6.5%)	54 (9.5%)	0.131
Renal disorder	Serum creatinine (median, IQR)	54 (46-64)	56 (48-71)	0.002 (0.017^a)
	24 h proteinuria ()			0.423
	Pathological classifications (I/II/III/IV/V, %)	0(0%)/4(5.3%)/21(28.0%)/23(30.7%)/27(36.0%)	1(0.8%)/14(11.2%)/18(14.4%)/49(39.2%)/43(34.4%)	0.086
Neurologic disorder (+, %)		18 (4.2%)	17 (3.0%)	0.304
Hematologic disorder	Hemolytic anemia (+, %)	9 (2.1%)	9 (1.6%)	0.544
	Leukopenia (+, %)	98 (23.5%)	149 (26.2%)	0.276
	Lymphopenia (+, %)	173 (41.7%)	230 (41.3%)	0.902
	Thrombocytopenia (+, %)	98 (23.6%)	145 (25.9%)	0.404
Immunologic disorder	Anti-dsDNA (+, %)	238 (61.8%)	331 (64.1%)	0.473
	Anti-Sm (+, %)	45 (14.2%)	87 (20.0%)	0.039 (0.042^b)
	C3			0.082
	C4			0.271
SLEDAI ()				0.601

^a value calculated using the quartile of serum creatinine under the logistic regression model. ^b value calculated under the logistic regression model.